首页> 外文期刊>Infectious Diseases and Therapy >In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens
【24h】

In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens

机译:聚维酮碘含漱液/漱口水对呼吸道和口腔道病原菌的体外杀菌和杀病毒功效

获取原文
           

摘要

IntroductionRecent virus epidemics and rising antibiotic resistance highlight the importance of hygiene measures to prevent and control outbreaks. We investigated the in vitro bactericidal and virucidal efficacy of povidone-iodine (PVP-I) 7% gargle/mouthwash at defined dilution against oral and respiratory tract pathogens. MethodsPVP-I was tested against Klebsiella pneumoniae and Streptococcus pneumoniae according to bactericidal quantitative suspension test EN13727 and against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses (SARS-CoV and MERS-CoV), rotavirus strain Wa and influenza virus A subtype H1N1 according to virucidal quantitative suspension test EN14476. PVP-I 7% gargle/mouthwash was diluted 1:30 with water to a concentration of 0.23% (the recommended concentration for “real-life” use in Japan) and tested at room temperature under clean conditions [0.3?g/l bovine serum albumin (BSA), viruses only] and dirty conditions (3.0?g/l BSA?+?3.0?ml/l erythrocytes) as an interfering substance for defined contact times (minimum 15?s). Rotavirus was tested without protein load. A?≥?5 log10 (99.999%) decrease of bacteria and?≥?4 log10 (99.99%) reduction in viral titre represented effective bactericidal and virucidal activity, respectively, per European standards. ResultsPVP-I gargle/mouthwash diluted 1:30 (equivalent to a concentration of 0.23% PVP-I) showed effective bactericidal activity against Klebsiella pneumoniae and Streptococcus pneumoniae and rapidly inactivated SARS-CoV, MERS-CoV, influenza virus A (H1N1) and rotavirus after 15?s of exposure. ConclusionPVP-I 7% gargle/mouthwash showed rapid bactericidal activity and virucidal efficacy in vitro at a concentration of 0.23% PVP-I and may provide a protective oropharyngeal hygiene measure for individuals at high risk of exposure to oral and respiratory pathogens. FundingMundipharma Research GmbH & Co. KG (MRG).
机译:简介最近的病毒流行和不断增加的抗生素耐药性凸显了卫生措施对预防和控制疾病暴发的重要性。我们研究了聚维酮碘(PVP-1)7%含漱液/漱口水在确定的稀释度下对口腔和呼吸道病原体的体外杀菌和杀病毒功效。方法按照EN13727定量定量悬浮试验,对PVP-1进行抗肺炎克雷伯菌和肺炎链球菌检测,并根据严重急性呼吸综合征和中东呼吸综合征冠状病毒(SARS-CoV和MERS-CoV),轮状病毒Wa和H1N1亚型流感病毒对PVP-1进行检测进行EN14476杀虫定量悬浮液测试。将PVP-I 7%含漱液/漱口水用水按1:30稀释至0.23%的浓度(日本“实际生活中的推荐浓度”),并在室温下于干净的条件下进行测试[0.3?g / l牛血清白蛋白(BSA),仅病毒]和肮脏条件(3.0微克/升BSAα+ 3.0微克/升红细胞)作为干扰物质,规定的接触时间(最少15微秒)。轮状病毒在无蛋白质负载的情况下进行了测试。细菌滴度下降≥5log 10 (99.999%),而滴度下降≥≥4log 10 (99.99%)表示有效的杀菌活性。分别按照欧洲标准。结果PVP-1漱口水/漱口水以1:30稀释(相当于0.23%PVP-1的浓度)显示出对肺炎克雷伯菌和肺炎链球菌的有效杀菌活性,并迅速灭活了SARS-CoV,MERS-CoV,A型流感病毒(H1N1)和暴露15秒后出现轮状病毒。结论PVP-I浓度为7%的漱口剂/漱口水在0.23%PVP-I的浓度下具有快速的体外杀菌活性和杀灭病毒的功效,并且可能为高暴露于口腔和呼吸道病原体的个体提供保护性的口咽卫生措施。资金Mundipharma Research GmbH&Co. KG(MRG)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号